Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

R. Saso; S. Kulkarni; P. Mitchell; J. Treleaven; G. J. Swansbury; J. Mehta; R. Powles; S. Ashley; A. Kuan; T. Powles

doi:10.1054/bjoc.2000.1196

Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

R. Saso, S. Kulkarni, P. Mitchell, J. Treleaven^*, G. J. Swansbury, J. Mehta, R. Powles, S. Ashley, A. Kuan, T. Powles

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Abstract

Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years. Median duration of survival from diagnosis of MDS/AML was 10 months and six patients died. The crude incidence of developing MDS/AML after MMM or MM chemotherapy was 15 per 100,000 patient years followup, while the actuarial risk was 1.1% and 1.6% at 5 and 10 years respectively. MTZ-based regimens carry a 10 x higher risk of subsequent MDS/AML compared to that seen in the general population. (C) 2000 Cancer Research Campaign.

Original language	English (US)
Pages (from-to)	91-94
Number of pages	4
Journal	British Journal of Cancer
Volume	83
Issue number	1
DOIs	https://doi.org/10.1054/bjoc.2000.1196
State	Published - 2000

Keywords

Acute myeloid leukaemia
Breast cancer
Mitoxantrone
Myelodysplastic syndrome

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1054/bjoc.2000.1196

Cite this

@article{c5a70b57c2ce4083a6c7490b210999c7,

title = "Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma",

abstract = "Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years. Median duration of survival from diagnosis of MDS/AML was 10 months and six patients died. The crude incidence of developing MDS/AML after MMM or MM chemotherapy was 15 per 100,000 patient years followup, while the actuarial risk was 1.1% and 1.6% at 5 and 10 years respectively. MTZ-based regimens carry a 10 x higher risk of subsequent MDS/AML compared to that seen in the general population. (C) 2000 Cancer Research Campaign.",

keywords = "Acute myeloid leukaemia, Breast cancer, Mitoxantrone, Myelodysplastic syndrome",

author = "R. Saso and S. Kulkarni and P. Mitchell and J. Treleaven and Swansbury, {G. J.} and J. Mehta and R. Powles and S. Ashley and A. Kuan and T. Powles",

year = "2000",

doi = "10.1054/bjoc.2000.1196",

language = "English (US)",

volume = "83",

pages = "91--94",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

AU - Saso, R.

AU - Kulkarni, S.

AU - Mitchell, P.

AU - Treleaven, J.

AU - Swansbury, G. J.

AU - Mehta, J.

AU - Powles, R.

AU - Ashley, S.

AU - Kuan, A.

AU - Powles, T.

PY - 2000

Y1 - 2000

N2 - Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years. Median duration of survival from diagnosis of MDS/AML was 10 months and six patients died. The crude incidence of developing MDS/AML after MMM or MM chemotherapy was 15 per 100,000 patient years followup, while the actuarial risk was 1.1% and 1.6% at 5 and 10 years respectively. MTZ-based regimens carry a 10 x higher risk of subsequent MDS/AML compared to that seen in the general population. (C) 2000 Cancer Research Campaign.

AB - Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years. Median duration of survival from diagnosis of MDS/AML was 10 months and six patients died. The crude incidence of developing MDS/AML after MMM or MM chemotherapy was 15 per 100,000 patient years followup, while the actuarial risk was 1.1% and 1.6% at 5 and 10 years respectively. MTZ-based regimens carry a 10 x higher risk of subsequent MDS/AML compared to that seen in the general population. (C) 2000 Cancer Research Campaign.

KW - Acute myeloid leukaemia

KW - Breast cancer

KW - Mitoxantrone

KW - Myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=0034079462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034079462&partnerID=8YFLogxK

U2 - 10.1054/bjoc.2000.1196

DO - 10.1054/bjoc.2000.1196

M3 - Article

C2 - 10883674

AN - SCOPUS:0034079462

SN - 0007-0920

VL - 83

SP - 91

EP - 94

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 1

ER -

Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this